MX2024013203A - Composiciones farmaceuticas y nutraceuticas con una combinacion de aminoacidos y su uso en enfermedades caracterizadas por la acumulacion de lipidos en los tejidos. - Google Patents

Composiciones farmaceuticas y nutraceuticas con una combinacion de aminoacidos y su uso en enfermedades caracterizadas por la acumulacion de lipidos en los tejidos.

Info

Publication number
MX2024013203A
MX2024013203A MX2024013203A MX2024013203A MX2024013203A MX 2024013203 A MX2024013203 A MX 2024013203A MX 2024013203 A MX2024013203 A MX 2024013203A MX 2024013203 A MX2024013203 A MX 2024013203A MX 2024013203 A MX2024013203 A MX 2024013203A
Authority
MX
Mexico
Prior art keywords
tissues
pharmaceutical
diseases characterized
combination
amino acids
Prior art date
Application number
MX2024013203A
Other languages
English (en)
Spanish (es)
Inventor
Bas Prior Josep Maria Del
Miró Xavier Escoté
Vázquez Sergio Quesada
Lemos José Manuel Fernández-Real
Perxachs Jordi Mayneris
Luque Julio Carlos Baudin
Palou Antoni Caimari
Llavinés Francesc Puiggròs
Nobau Ana Castells
Original Assignee
Fund Eurecat
Fundacio Inst Dinvestigacio Biomedica De Girona Dr Josep Trueta
Consorcio Centro De Investig Biomedica En Red
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fund Eurecat, Fundacio Inst Dinvestigacio Biomedica De Girona Dr Josep Trueta, Consorcio Centro De Investig Biomedica En Red filed Critical Fund Eurecat
Publication of MX2024013203A publication Critical patent/MX2024013203A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
MX2024013203A 2022-04-25 2024-10-25 Composiciones farmaceuticas y nutraceuticas con una combinacion de aminoacidos y su uso en enfermedades caracterizadas por la acumulacion de lipidos en los tejidos. MX2024013203A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22382390 2022-04-25
PCT/EP2023/060827 WO2023208944A1 (en) 2022-04-25 2023-04-25 Pharmaceutical and nutraceutical compositions with a combination of amino acids and its use in diseases characterized by lipid accumulation in tissues

Publications (1)

Publication Number Publication Date
MX2024013203A true MX2024013203A (es) 2025-02-10

Family

ID=81579974

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024013203A MX2024013203A (es) 2022-04-25 2024-10-25 Composiciones farmaceuticas y nutraceuticas con una combinacion de aminoacidos y su uso en enfermedades caracterizadas por la acumulacion de lipidos en los tejidos.

Country Status (7)

Country Link
US (1) US20250268855A1 (cg-RX-API-DMAC7.html)
EP (1) EP4514147A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025515358A (cg-RX-API-DMAC7.html)
CN (1) CN119343061A (cg-RX-API-DMAC7.html)
CA (1) CA3249636A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024013203A (cg-RX-API-DMAC7.html)
WO (1) WO2023208944A1 (cg-RX-API-DMAC7.html)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) * 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
US11246846B2 (en) * 2017-10-23 2022-02-15 Michael S. Tempesta Trisodium citrate compositions having enhanced uptake across digestive mucosa

Also Published As

Publication number Publication date
EP4514147A1 (en) 2025-03-05
CN119343061A (zh) 2025-01-21
CA3249636A1 (en) 2023-11-02
JP2025515358A (ja) 2025-05-14
WO2023208944A1 (en) 2023-11-02
US20250268855A1 (en) 2025-08-28

Similar Documents

Publication Publication Date Title
Nirmal et al. Valorization of fish byproducts: sources to end‐product applications of bioactive protein hydrolysate
JP7104018B2 (ja) コラーゲンペプチド含有組成物の苦味マスキング方法
CN112399799A (zh) 脂肪蓄积抑制用组合物
MY177974A (en) A pharmaceutical composition for prevention of diet induced obesity
JP6222663B2 (ja) 筋委縮抑制剤
Jeelani et al. The therapeutic potential of chia seeds as medicinal food: A review
JP2009159983A (ja) 食品組成物
CA2521967A1 (fr) Composition nutritionnelle ou therapeutique contenant le compose oleurofeine ou l'un de ses derives
JP2014504261A5 (cg-RX-API-DMAC7.html)
ES2544894T3 (es) Hidrolizados de proteínas animales de origen marino con propiedades neuroprotectoras
JP2006304792A (ja) 内臓脂肪蓄積抑制食品
JP7188936B2 (ja) 抗炎症剤
JP6393501B2 (ja) 多価不飽和脂肪酸含有油脂の風味改善剤
WO2006109194A3 (en) Chromium-fatty acid compounds and methods of making and using thereof
WO2011145307A1 (ja) アディポネクチン産生促進組成物
JP2010270030A (ja) 抗菌ペプチドの発現誘導剤または分泌促進剤
JP6901597B2 (ja) アスタキサンチン含有組成物
JP2014210792A (ja) 経口組成物
JP6483244B2 (ja) 蜂の子を含有する滋養強壮剤
MX2022010949A (es) Composiciones de avenantramida con solubilidad mejorada que comprenden 4-hidroxifenona.
JP6514500B2 (ja) 関節痛及び腰痛改善剤
MX2019015712A (es) Formas cristalinas de beta-sitosterol.
JP2014224074A (ja) ヤナギ科ヤナギ属植物の抽出物を含有するエラスターゼ活性抑制剤
WO2019232493A1 (en) Hempseed oil compositions
RU2402942C1 (ru) Биологически активная добавка к пище, обладающая гепатопротекторными свойствами